About the Authors
- Marie-Clotilde Bernard
-
* E-mail: marie-clotilde.bernard@sanofipasteur.com
Affiliation Sanofi Pasteur, Research and Development, Marcy-l’Étoile, France
- Véronique Barban
-
Affiliation Sanofi Pasteur, Research and Development, Marcy-l’Étoile, France
- Fabrine Pradezynski
-
Affiliation Sanofi Pasteur, Research and Development, Marcy-l’Étoile, France
- Aymeric de Montfort
-
Affiliation Sanofi Pasteur, Research and Development, Marcy-l’Étoile, France
- Robert Ryall
-
Affiliation Sanofi Pasteur, Research and Development, Swiftwater, Pennsylvania, United States of America
- Catherine Caillet
-
Affiliation Sanofi Pasteur, Research and Development, Marcy-l’Étoile, France
- Patricia Londono-Hayes
-
Affiliation Sanofi Pasteur, Research and Development, Marcy-l’Étoile, France
Competing Interests
The authors confirm that all authors are employees of Sanofi Pasteur, which is developing the HSV529 vaccine for herpes. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. The authors declare that the vaccine described in the article is a product in development at Sanofi Pasteur and that this work was conducted as part of a larger HSV vaccine project.
Author Contributions
Conceived and designed the experiments: PLH VB MCB ADM. Performed the experiments: FP MCB. Analyzed the data: ADM MCB CC. Contributed reagents/materials/analysis tools: FP ADM RR MCB VB. Wrote the paper: MCB.